AveXis, a Dallas, Texas-based gene therapy-focused biotech company, raised $10m in funding.
The round was led by Deerfield Management and Roche Venture Fund. In conjunction with the funding, Jonathan Leff of Deerfield and Carole Nuechterlein of Roche Venture Fund joined AveXis’ board of directors.
The company intends to use the funds to further the development of its gene therapy product, chariSMATM, including additional support for the current Phase I clinical trial in SMA Type 1 infants.
Led by John A. Carbona, Chief Executive Officer, AveXis focuses on using gene therapy to improve care for patients with severe genetic and orphan diseases like Spinal Muscular Atrophy (SMA).